Outlook Therapeutics Establishes New $100M ATM Program, Reports $12.2M Preliminary Cash

summarizeSummary

Outlook Therapeutics has established a new $100 million At-The-Market offering program and reported a preliminary cash balance of $12.2 million, providing crucial liquidity amidst ongoing financial challenges.

check_boxKey Events

• New At-The-Market (ATM) Offering Program

  The company entered into a new ATM offering agreement with H.C. Wainwright & Co., LLC, authorizing it to issue and sell shares of common stock with an aggregate offering price of up to $100,000,000 from time to time. This program replaces a prior $100,000,000 ATM agreement with BTIG, LLC, which was terminated.

• Preliminary Cash Position Update

  Outlook Therapeutics reported preliminary unaudited cash and cash equivalents of approximately $7.7 million as of March 31, 2026. This amount increases to $12.2 million after including $4.5 million in net proceeds from a registered direct equity offering completed in April 2026.

• Ongoing Financial and Regulatory Context

  This capital markets activity occurs as the company faces significant financial challenges, including a previously reported net loss, negative revenue, and substantial doubt about its ability to continue as a going concern, as well as a Nasdaq bid price non-compliance notice.

auto_awesomeAnalysis

Outlook Therapeutics has replaced its existing At-The-Market (ATM) offering program with a new one, maintaining the authorization to issue up to $100 million in common stock. This provides the company with continued access to capital, which is critical given its recent disclosures of a significant net loss, negative revenue, and substantial doubt about its ability to continue as a going concern. The filing also provides an updated preliminary cash position of $12.2 million, including recent offering proceeds, offering a clearer, albeit unaudited, picture of its short-term liquidity.